CN107312851A - Myocardial infarction biomarker miR 1283 - Google Patents

Myocardial infarction biomarker miR 1283 Download PDF

Info

Publication number
CN107312851A
CN107312851A CN201710592044.1A CN201710592044A CN107312851A CN 107312851 A CN107312851 A CN 107312851A CN 201710592044 A CN201710592044 A CN 201710592044A CN 107312851 A CN107312851 A CN 107312851A
Authority
CN
China
Prior art keywords
mir
myocardial infarction
mirna
target gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201710592044.1A
Other languages
Chinese (zh)
Inventor
孙锦云
李曙光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Yangshen Biomedical Co Ltd
Original Assignee
Beijing Medintell Bioinformatic Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Medintell Bioinformatic Technology Co Ltd filed Critical Beijing Medintell Bioinformatic Technology Co Ltd
Priority to CN201710592044.1A priority Critical patent/CN107312851A/en
Publication of CN107312851A publication Critical patent/CN107312851A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to myocardial infarction biomarker miR 1283, and in particular to the application of miR 1283 and its target gene in diagnosis and treatment myocardial infarction.MiRNA is less in the expression of acute myocardial infarction AMI and possible Effect study, existing biomarker far can not meet clinical diagnosis demand, the present invention picks out miR 1283 and its target gene HDAC4, PHC2, THOC5, IL17RA based on high-throughput techniques, confirmatory experiment shows that they can be used for the clinical diagnosis and prevention detection of myocardial infarction, and the present invention lays the foundation for the research and development of clinically myocardial infarction dependent diagnostic reagent.

Description

Myocardial infarction biomarker miR-1283
Technical field
The present invention relates to medical diagnosis on disease therapy field, myocardial infarction biomarker miR-1283 is specifically related to, more Body is related to the application of miR-1283 and its target gene in diagnosis and treatment myocardial infarction.
Background technology
Acute myocardial infarction AMI (AMI) is a kind of angiocardiopathy of most serious, and early stage, accurately diagnosis can ensure to fill again What note was treated immediately begins to be likely to reduced the death rate.The application of some biomarkers such as cardiac muscle troponin I and diagnosis AMI, Current diagnosis can be improved, is the new method of acute myocardial infarction AMI.However, miRNA is in the expression of acute myocardial infarction AMI and possible Effect is that research is less, and conventional research shows that miR-30a is, miR-195 target gene regulation cell related to myocardial hypertrophy Apoptosis, cell propagation and the cell cycle, they can as diagnosing acute myocardial infarction biomarker potential clinical value, but It is that these are also far from enough, clinical accurate diagnosis and treatment needs more candidate molecules marks.
Existing research show the neurological susceptibility of miR-1283 precursor and HBV associated hepatocellular carcinomas it is significantly correlated (miRNA-SNPs's Genetic association is studied and the Integrative Biology of liver cancer is studied, 2011 thesis for the doctorate, Chinese People's Liberation Army's military medicine science Institute), in addition, miR-1283 low expressions in non-tuberculous mycobacteria the infected's blood plasma, are potentially to differentiate tuberculosis branch Bacillus infection and the molecular marker of mycobacterium tuberculosis infection (tuberculosis and difference table in non-tuberculous mycobacteria the infected's blood plasma Up to microRNAs screenings, modern preventive medicine, 2016).The present invention is based on high-flux sequence method, obtains myocardial infarction miRNA With mRNA expression data, meanwhile, with reference to GEO database hub fleshes infarct correlation miRNA and mRNA data, carry out biological information Credit analysis checking, picks out miR-1283 from the miRNA and mRNA of candidate and its target gene carries out molecular biology checking, knot Fruit display, miR-1283 and its target gene and myocardial infarction are closely related.Clinical diagnosis and prevention inspection available for myocardial infarction Survey, be that clinically the research and development of dependent diagnostic reagent lay the foundation.
The content of the invention
Detect application of the miR-1283 preparation in diagnosing myocardial infarction reagent is prepared.
The sequence of the miR-1283 is shown in sequence table SEQ ID NO 1.
Further, diagnosing myocardial infarction reagent include based on high-flux sequence method and/or based on quantifying PCR method and/ Or based on miR-1283 in probing procedure detection sample.
It is preferred to use northern hybridizing methods, miRNA chip of expression spectrum, ribozyme protection analytical technology, RAKE methods, original position MiR-1283 transcription in hybridization, bead-based flow-cytometry detection sample.
Described sample is peripheral blood.
It is preferred that, specific amplification miR-1283 primer is included based on quantifying PCR method, further preferably, specificity The primer sequence for expanding miR-1283 is SEQ ID NO 2;Nucleotide sequence with miR-1283 is included based on probing procedure The probe of hybridization.
It is an object of the invention to provide application of the miR-1283 target gene in diagnosing myocardial infarction preparation is prepared.
The target gene be DIANA-MICROT, MICRORNA.ORG, MIRDB, RNA22-HAS, TARGETMINER, MiR-1283 target genes disclosed in TARGETSCAN-VERT databases.
It is preferred that, the target gene is HDAC4, PHC2, THOC5, IL17RA.
Further, diagnosing myocardial infarction reagent include based on high-flux sequence method and/or based on quantifying PCR method and/ Or the transcription of sample miR-1283 target genes is detected or based in immunologic detection method detection sample based on probing procedure The expression of miR-1283 target genes.
It is preferred to use northern hybridizing methods, miRNA chip of expression spectrum, ribozyme protection analytical technology, RAKE methods, original position The transcription of miR-1283 target genes in hybridization, bead-based flow-cytometry detection sample;Using ELISA and/or collaurum The expression of miR-1283 target genes in ELISA test strip sample.
Exist it is an object of the invention to provide the active reagent of up-regulation miR-1283 transcription and/or promotion miR-1283 Prepare the application prevented and treated in myocardial infarction preparation.
It is preferred that, using the microRNA gain-of-functions technology based on RNA and/or gene specific miR Mimics skills Art up-regulation miR-1283 transcription and/or the activity for promoting miR-1283.It is preferred that artificial synthesized short hairpin RNA or by regulation and control open Mover raises miR-1283.
It is an object of the invention to provide the inhibitor of miR-1283 target gene in preparation prevents and treats myocardial infarction preparation Application.
It is an object of the invention to provide a kind of myocardial infarction diagnosis reagent, myocardial infarction diagnosis reagent can detect cardiac muscle MiR-1283 transcription or immunologic detection method detect the target gene that miR-1283 regulates and controls in myocardial infarction sample in infarct sample Expression.
Further, myocardial infarction diagnosis reagent include detection miRNA regulation and control target gene HDAC4, PHC2, THOC5, The specific primer of IL17RA expression.
Myocardial infarction treatment medicine or examination are being prepared it is an object of the invention to provide the above-mentioned preparation for preventing and treating myocardial infarction Application in agent.
Definition:
The method of detection miRNA expression is mainly included based on high throughput sequencing technologies, based on nucleotides at this stage Hybridization and the miRNA detection methods of PCR-based.MiRNA detection methods based on probe hybridization technique are a kind of direct Detection Methods, Sample rna need not in advance be expanded, including northern hybridizing methods, miRNA chip of expression spectrum, ribozyme protection analysis skill The technologies such as art, RAKE methods, in situ hybridization, bead-based flow-cytometry.
(1) Northern hybridizes
Also known as Northern blot is most classical detection eucaryote RNA sizes, estimates the experimental method of its abundance.Base Present principles are as follows:MiRNA samples are fixed on carrier (such as silicon chip, microballoon or film) first, then it is miscellaneous with the probe of process mark Hand over, signal detection is carried out after washing unnecessary hybridization probe;Can also the first fixed and target miRNA sequence complementation on carrier DNA probe, then with the sample miRNA hybridization by mark, then carries out signal detection.The method of signal mark includes isotope Mark, fluorescence labeling and nano gold mark etc..
(2) miRNA chip of expression spectrum
Principle is equally that the target molecule on solid support is detected using label probe.Pass through miRNA in design chips Gene and internalcontrol sequence, can Accurate Analysis go out the expression of corresponding miRNA in sample.Genetic chip has high-throughout excellent Point, can once detect whole expression of hundreds of genes in same sample.The liquid-phase chip that Luminex companies develop (Liquid chip) is also known as multifunctional suspending dot matrix (Multi analyte suspension array, MASA), is new Generation biochip technology.Liquid-phase chip system is made up of many spherulas for main matrix, is fixed with not on every kind of spherula With probe molecule, in order to distinguish different probes, sphere matrix that each is used for label probe is all unique with one Color numbers, these spherulas are suspended in a liquid-phase system, liquid-phase chip system is just constituted.The system can be to same Multiple different moleculars in one trace sample carry out quick qualitative and quantitative analysis simultaneously, and this detection technique is referred to as FMAP (Flexible multianalyte profiling) technology.Molecule hybridization is carried out in aaerosol solution, detection speed pole It hurry up.
(3) ribozyme protection analytical technology (RPA)
MiRNA detection can also protect analytical technology using ribozyme, and the probe marked and RNA samples to be measured are mixed Close, hybridize after thermal denaturation, non-hybridized RNA and the single-chain nucleic acid enzymic digestion of unnecessary probe, purify after heat inactivation nuclease by The RNA molecule of protection, finally by denaturation PAGE electrophoretic separation probes, colour developing.This new method based on solution hybridization is simple Quickly, sensitivity is high, but is also only used for analyzing known miRNA.
(4) RAKE methods
RAKE methods (RNA primed array based Klenow emzyme) are the bases in miRNA microarray The Klenow fragments of DNA polymerase i are utilized on plinth, make miRNA and the method for fixed DNA probe hybridization.RAKE can be sensitive Specifically detect miRNA, it is adaptable to largely quickly screen all miRNA that oneself knows.Can be in specific cell and tumour Detect miRNA express spectra situations.Moreover, RAKE methods can also be from the tissue of the FFPE secured by formalin Isolate miRNA and it is analyzed, be the door that analysis miRNA opens hope from sample is achieved.
(5) in situ hybridization (in situ hybridization)
Hybridization in situ technique can intuitively understand miRNA expression ways, be a kind of easier of observation miRNA spatial and temporal expressions Method, normal mark mode includes digoxin, biotin, fluorescence labeling etc..In situ hybridization (Locked on the basis of locked nucleic acid Nucleic Acid (LNA) based in situ hybridization (LNA-ISH)) it is the more probe side of current application Formula.
(6) bead-based flow-cytometry (bead-based flow cytometry)
It is a kind of liquid-phase chip technology, FCM analysis is organically combined, had concurrently by this method with chip technology Flux is big, detection speed is fast, sensitivity is high and it is specific good the features such as.
(7) Real-Time Fluorescent Quantitative PCR Technique (Real-time PCR, RT-PCR)
Fluoroscopic examination PCR instrument can draw dynamic changing curve to the cumulative speed of extension increasing sequence during whole PCR.Anti- Answer the initial concentration of target sequence in mixed system bigger, it is desirable to which the PCR cycle number for obtaining amplified production specific output is (general to use Specific threshold period Ct is expressed) it is fewer.Because miRNA length is only 22nt, it is such that traditional qRT-PCR is not suitable for amplification Short fragment.There are several real time quantitative PCR methods for miRNA, such as tailing method, neck ring method now.Neck ring method is a kind of Preferable miRNA detections qRT-PCR methods:Special loop-stem structure primer is designed first, using miRNA to be measured as template reverse transcription The chains of cDNA first are synthesized, the cDNA one end is stem Loop primer, and stem loop structure, which is opened, substantially increases cDNA length, then Real-time quantitative PCR amplification is carried out by template design primer of the cDNA of synthesis.QRT-PCR has specificity height, sensitivity good, fast A variety of advantages such as fast simple.
(8) PCR sequencing PCR
Most of known miRNA is to be sequenced to find and identify by cDNA clone.The method needs first to build miRNA CDNA library, then enter performing PCR amplification, amplified production be then cloned on expression vector be sequenced.Takada develops one kind and changed The amplification PCR cloning PCR (miRNA amplification profiling, mRAP) entered, mRAP methods are first connected at miRNA 3 ' ends Joint, then with the reverse transcription primer reverse transcription complementary with joint.Because specific reverse transcriptase has end deoxynucleotide Transferase active, some nucleotides (mainly deoxycytidylic acid) can be connected to 3 ' ends of the cDNA chains that reverse transcription goes out.When 5 ' End connector is the achievable PCR expansions to cDNA with after poly (C) cohesive end annealing of cDNA chains, adding a pair of general primers Increase.Due to mRAP High sensitivities, the expression quantity of miRNA in a small amount of tissue can be directly detected with clone and sequencing technologies.Label Sequence PCR cloning PCR is a kind of to have developed detection efficiency on the basis of serial analysis of gene expression (SAGE) technology higher MiRAGE (miRNA SAGE) PCR cloning PCR, the method sub-series big by generating can detect multiple by single sequencing reaction MiRNA, hence it is evident that improve detection efficiency.
High-flux sequence (High-throughput sequencing) is also known as sequencing technologies (next of future generation Generation sequencing) it is the change to tradition sequencing revolution, once to hundreds of thousands to millions of DNA Molecule carries out sequencing, greatly improves sequencing efficiency.This kind of large scale sequencing technology greatly improves multiple species and lost The solution reading rate of information is passed, to obtain all miRNA sequence information, decryption miRNA collection of illustrative plates, which is provided, to be ensured.While high flux The analysis for make it that careful overall picture is carried out to the transcript profile and genome of a species is sequenced, so the depth that is otherwise known as It is sequenced (deep sequencing).The representative of high-flux sequence platform is 454 sequenator (Roch of Roche Holding Ag (Roche) GSFLX sequencer), the Solexa genome analysises instrument (Illumina Genome Analyzer) of Illumina companies and ABI SOLiD sequenators (ABI SOLiD sequencer).
MicroRNA gain-of-functions technology based on RNA be by exogenous supplement miRNAs synthesis precursor substance come Raise miRNAs level.For example, can be with the artificial synthesized bob folder sample RNA (short consistent with endogenous miRNA sequence Hairpin RNA, shRNA), promoter is done by polymerase II or III, with virus for carrier transfectional cell, by Dicer enzyme modifications RISC is loaded into afterwards to play a role, it is lasting equivalent to rise pre-miRNA level, action effect stabilization.
This technique avoids the nonspecific action of miRNA and gene for gene specific miR Mimics technologies.This people The specific oligonucleotide chain combined with the UTR of target gene 3 ' complementations of work synthesis, can be played with being adjusted after the transcription of miRNA identicals Section is acted on.
The major way of miRNA regulation and control has two kinds:A kind of is the not fully complementary pairings of 3 ' UTR with target gene mRNA, resistance The translation of disconnected target gene, so that regulatory gene is expressed;It is another be it is similar with siRNA, when miRNA and mRNA complete complementaries are matched When, Ago2 albumen directly results in its degraded by cutting mRNA, realizes gene silencing.In a word, miRNA is presently believed to which kind of side Formula is acted on target gene and miRNA is relevant with the pairing degree of target gene.When miRNA matches incomplete with target gene, MiRNA is just played a role with the expression for suppressing target gene;When miRNA matches complete with target gene section sequence, it is possible to Target gene is caused to be broken in complementary region and cause gene silencing.
Brief description of the drawings
Fig. 1 is the ROC curve figure of miR-1283 diagnosing myocardial infarctions
Fig. 2 is miR-1283 relative expression's situation maps
Fig. 3 is HDAC4, PHC2, THOC5, IL17RA gene relative expression's situation map
Embodiment
With reference to specific embodiment, the present invention is expanded on further, is only used for explaining the present invention, and it is not intended that to this The limitation of invention.It will be understood by those skilled in the art that:Can in the case where not departing from the principle and objective of the present invention So that these embodiments are carried out with a variety of change, modification, replacement and modification, the scope of the present invention is limited by claim and its equivalent It is fixed.The experimental method of unreceipted actual conditions in the following example, generally according to normal condition or according to the bar proposed by manufacturer Part examinations.
The collection of the sample of embodiment 1 and Total RNAs extraction
Hospital in March, 2015 is collected each 6 to the myocardial infarction patient of in September, 2016 peripheral bloods and normal healthy controls peripheral blood. Diagnosis of Acute Myocardial Infarction standard:According to third time in 2012《Myocardial infarction whole world unified definition》The diagnostic criteria system of recommendation It is fixed.Detect myocardial necrosis marker (mainly troponin) level to rise and/or decline, at least 1 time more than reference value 99%th percentile of the upper limit, and at least with the symptom of a following ischemic.
1) symptom of myocardial ischemia;
2) the ischemic ECG of kainogenesis changes;
3) there are pathologic Q ripples in electrocardiogram;
4) radiological evidence shows new myocardial activity and lost or new regional wall motion abnormality;
5) coronarography or postmortem find there is fresh thrombus in coronary artery.
Blood rna extraction standard:RNA purity:OD260/280≤1.8,28S/18S≤1;RNA integralities:RIN Zhi≤ 7.0.RNA integrality detection methods:(agarose coagulates for Agilent 2100 (RNA 6000Nano kit), agarose gel electrophoresis Gum concentration:1% agarose gel;Voltage:5V/cm;Time:20min).
Embodiment 2 is sequenced, data analysis and electronically validating
Sequencing:MiRNA and mRNA is carried out with llumina Hiseq2500/Miseq second generations high throughput sequencing technologies Sequencing, by go joint, go low quality, the process such as depollute completes the processing of data, obtains final data.Pass through transcript profile number Progress t-test after background correction is carried out to miRNA and mRNA sequencing initial data according to analysis software and obtains P values, is then utilized Fisher, which is examined, merges P values, screening differential expression miRNA and mRNA.Using including miRanda, miRDB, miRWalk and These algorithm forecasted varianceses of Targetscan express miRNA target gene, choose >=4 algorithms and predict the target gene come, and The miRNA for the differential expression being had verified that in miRWalk database lookups target gene.
It is final selected from the differential expression miRNA and mRNA of candidate to miR-1283 and its target gene HDAC4, PHC2, THOC5, IL17RA, progress later experiments checking.
The electronically validating of embodiment 3
Electronically validating:3 sets of mRNA data sets are obtained from the screening of GEO (Gene Expression Omnibus) database (GSE48060, GSE34198 and GSE61145-GPL6884) and 2 sets of miRNA data sets (GSE61741, GSE31568), 3 sets MRNA data sets (GSE48060, GSE34198 and GSE61145-GPL6884) have gene 13680, we by using MetaMA bags, which are calculated and merged using merging P value methods, obtains 612 (FDR after effect value<0.05) difference expression gene, wherein on 352 are adjusted, 260 are lowered;The common miRNA numbers 848 of 2 sets of data collection (GSE24371, GSE17498).Use R bags MetaMA merges the analysis of P values to two sets of miRNA data sets, finds 15 differential expression miRNA (FDR<0.001&&| Combined.ES|>1).As a result show that electronically validating result is consistent with sequencing result expression trend.
It is to set up Receiver Operating Characteristics for single miRNA molecule or the method for the efficiency evaluation of diagnostic model (receiver operating characteristic, ROC) curve, passes through (the Area Under of area under calculated curve Curve) come judge diagnosis ability.Area value under ROC curve is between 1.0 and 0.5, in AUC>In the case of 0.5, AUC Closer to 1, illustrate that diagnosis effect is better, AUC has relatively low accuracy in 0.5-0.7, AUC is fixed in 0.7-0.9 True property, has high accuracy when AUC is more than 0.9.We will utilize GSE31568 data sets (including 70 control groups and 20 Example case group), and then analyzed, as a result show, the AUC of miR-1283 diagnosing myocardial infarctions is 0.886 (see Fig. 1), display Its accuracy rate is higher, show miR-1283 can as diagnosing myocardial infarction molecular marker.
The collection of the sample of embodiment 4 and the extraction of total serum IgE
1 sample collection:
36 myocardial infarction patients and 22 normal healthy controls crowd peripheral bloods (acquisition time in January, 2014-2015 year 8 Month).
2 Total RNAs extractions:
The processing for removing Rnase of related experiment article:
1. it will be rinsed before the application of all glasswares with DEPC and invade bubble, 120 DEG C of high pressure 20min, 180 DEG C of high temperature dry 2 More than hour.
2. by plastic ware (such as:EP pipes/pipette tips) need before use to be stayed overnight with 0.1%DEPC water enchroachment (invasion)s bubble, after drain liquid, 120 DEG C of high pressure 20min, baking box is dried standby.
Leucocyte is separated
(1) 2m1 anticoagulation cirumferential bloods are taken (blood sampling time is no more than 3h);
(2) isometric sterile PB S are added to be sufficiently mixed in peripheral blood, cell suspension is formed;
(3) 4m1 lymphocyte separation mediums are added in another centrifuge tube;
(4) draw 4m1 cell suspensions be gently added to along tube wall lymphocyte separation medium surface (note not with lymphocyte Separating liquid is mixed).Centrifuge 1500rpm 20min;
(5) boundary layer (tunica albuginea) is gently suctioned out with suction pipe to enter in another centrifuge tube.Sterile cold PBS is washed 2 times, is washed for last 1 time Washing can move into cell suspension in EP pipes, and supernatant is removed in centrifugation, for extracting RNA.
RNA is extracted
(1) sample is taken out in -80 DEG C of refrigerators, is shredded, Trizol is added in EP pipes in 1ml/50-100mg ratio, Homogenized is carried out, 5-l0min is stored at room temperature;
(2) every milliliter of Trizol adds 0.2m1 chloroforms, acutely shakes 15s, is stored at room temperature 2-3min, 12000 at 4 DEG C Leave heart 15min;
(3) the careful supernatant water 600ul that makes an appointment that suctions out moves into another centrifuge tube (being careful not to be extracted into albumin layer), adds equivalent Isopropanol, overturns and mixes, be stored at room temperature 10min;
(4) 4 DEG C of 12000g centrifuge l0min, abandon supernatant, bottom visible white material;
(5) the rotation washing of the cold ethanol of lml 75% is added, isopropanol is cleaned;
(6) 4 DEG C of 12000g centrifuge 5min, remove the 5-l0min that dried in the air after ethanol, translucent, are dissolved with 20u1DEPC water RNA.3u1RNA samples are taken, the electrophoresis in 1.5% Ago-Gel;Lu1RNA samples in UV spectrophotometer measuring concentration, RNA samples in 1.8-2.0 are considered as with A260/280 qualified.
The RT-PCR of embodiment 5 detects miR-1283 and HDAC4, PHC2, THOC5, IL17RA expression
1 RT-PCR detects miR-1283 expression
Reverse transcription
The preparation of RT systems:1 μ g total serum IgEs are used as template ribonucleic acid;5×miScript HiSpec Buffer 4μl;10× Nucleics Mix 2μl;miScript Reverse Transcriptase Mix 2μl;Aqua sterilisa filling-in is to 20 μ l.ABI After 37 DEG C of insulation 60min make reverse transcription reaction complete in 9700 type PCR instruments, 95 DEG C of 5min terminating reactions.Add 80 μ l Nuclease-free H2O is diluted to 100 μ l, and to be stored in -20 DEG C of refrigerators standby.
Quantitative fluorescent PCR
The preparation of miRNA RT-PCR systems:
Reaction system:MiRNAs detection of expression sets 3 parallel tube reactions every time, and internal reference is used as using snRNA U6.Expand Increasing program:95℃10min;40 circulations (95 DEG C of 10s, 60 DEG C of 30s).
2 RT-PCR detection target genes HDAC4, PHC2, THOC5, IL17RA expression
Reverse transcription
UsingIII Reverse Transcriptase (invitrogen, article No. 18080-044) enter Row cDNA reverse transcriptions.Using Reverse Transcriptase kit, converse record synthesis cDNA is carried out to l μ g total serum IgEs with RT Buffer.RT bodies The preparation of system:5 × RT Buffer, 5 μ l, 10mmol/l dNTP, 1.25 μ l, 0.1mmol/l DTT 2.5 μ l, 30 μm of mol/ 2 μ l, 200U/ μ l MMLV of l OligodT 1.25 μ l, the μ g of template ribonucleic acid 1, add aqua sterilisa to the μ l of total system 25.42 DEG C of incubations 1 hour, 72 DEG C 10 minutes, of short duration centrifugation.CDNA is preserved and is put the standby RNA of -20 DEG C of refrigerators.
Quantitative fluorescent PCR
Sequence HDAC4 (NM_006037.3), PHC2 (NM_001330488.1), the THOC5 provided according to GenBank (NM_001002877.1), IL17RA (NM_001289905.1) designs primer, send company to be synthesized.
The preparation of mRNA RT-PCR systems:
Component Addition
2×mix 10μl
Sense primer 10uM 0.5μl
Anti-sense primer 10uM 0.5μl
Template 2μl
Add sterile purified water To 25 μ l
Reaction system:Use PowerGreen PCR Master Mix (invitrogen, article No. 4367659) enter Row amplification, interior participation in the election GAPDH, experimental implementation is carried out by product description.Amplification program is:95 DEG C of 10min, (95 DEG C of 15s, 55 DEG C 60s) × 35 circulations.
3 statistical analysis
Real-time quantitative PCR sample amplified production solubility curve is all unimodal, illustrates that amplified production only has one, is specificity Amplification;Amplification curve flex point understands that amplification curve entirety collimation is good, shows that the amplification efficiency of each reaction tube is close, and the limit is put down And without raising up now, exponent phase slope is larger, illustrates that amplification efficiency is higher;According to qRT-PCR relative quantification formula meter Experimental group and the multiple proportion of control group destination gene expression are calculated, compares tables of the miR-1283 in myocardial infarction group and control group Up to level.As a result show:MiR-1283 is about 0.3 times of control group in the expression quantity of illness group, HDAC4, PHC2, THOC5, IL17RA is at 2.6 times, 2.3 times, 2.2 times and 2.5 times that the expression quantity of illness group is control group, and result above demonstrates high flux The result of sequencing data analysis.
The culture and transient transfection of the cardiac muscle cell of embodiment 6
First, material prepares:
People's primary cardiomyocytes (Human Cardiac Myocytes, HCM) are purchased from ScienCell companies of the U.S., culture In special myocardial cells culture base.
LipofectamineTM2000Transfection Reagent(Invitrogen)。
MiR-1283 sequences issue Synesis Company, ask its chemical synthesis miR-1283mimics, miR-1283inhibitor And its non specific control.
2nd, experimental method
1 miRNA is transiently transfected
Lipofectamine is pressed in operationTM2000 reagent specifications are carried out.24h is thin by the good HCM of growth conditions before transfection Born of the same parents are inoculated into 6 orifice plates, and cell count is about 4 × 105/ L, cellar culture to transfect the same day, cell fusion degree be 70-80% when Tested.100nM miR-1283mimics/miR1283inhibitor are added in 250 μ l opti-MEM culture mediums, It is soft to mix;It is another to dilute 5 μ l Lipofectamine with 250 μ l opti-MEM culture mediumsTM2000 liposomes, it is soft to mix, It is incubated at room temperature 5min;Opti-MEM- liposomes and Opti-MEM-miRNAs are mixed, 20min is incubated at room temperature, it is multiple to form transfection Compound:Then said mixture is added in cell culture medium, gently mixed, complete medium is changed after culture 6h.Wherein, it is non- Specific mimics Negative Control (mimics NC) and inhibitor Negative Control (inhibitor NC) sequence is used as control.Cell total rna is extracted after culture 24-48h, and reverse transcription is into cDNA, real-time quantitative PCR The change that miR-1283 is expressed after detection is transiently transfected.
2 experimental results
Transiently transfected using cationic-liposome method, respectively by miR-1283mimics or miR- 1283inhibitor and corresponding control sequence Negative Control (NC) transfection cardiac muscle cell's strain HCM.Transfect after 48h, take out Carry cell total rna.Using U6 as internal reference, real-time quantitative PCR detects miR-1283 expression.As a result show:Compared with control group, After HCM transfections miR-1283mimics, miR-1283 expression increases about 3.8 times;Transfect after miR-1283inhibitor, Expression have dropped nearly 59%.Result above shows, can by transiently transfecting miR-1283mimics and miR-1283inhibitor Effectively up-regulation or downward miR-1283 expression, reliable results can carry out subsequent experimental.
Embodiment 6 transfects influences of the miR-1283 to Human Cardiomyocytes HDAC4, PHC2, THOC5, IL17RA gene expression
MiR-1283mimics or miR-1283inhibitor and corresponding control sequence Negative will be transiently transfected HCM cells after Control (NC) are inoculated into 96 orifice plates, after transfection 48h, extract cell total rna.Using GAPDH as internal reference, Real-time quantitative PCR detects HDAC4, PHC2, THOC5, IL17RA expression.
As a result show:Compared with control group, after HCM transfections miR-1283mimics, HDAC4, PHC2, THOC5, IL17RA Expression quantity reduce about 19%, 16%, 13% and 15% respectively, after transfection miR-1283inhibitor, HDAC4, PHC2, THOC5, IL17RA expression quantity rise about 17%, 13%, 10% and 11% respectively, preliminary proof miR-1283 and HDAC4, PHC2, THOC5, IL17RA targeting relation.
Although describing the present invention with reference to various preferred embodiments, it will be appreciated by those skilled in the art that can carry out each Change is planted, and available equivalents substitute base region of its component without departing from the present invention.Come in addition, many changes can be carried out Particular case or material is set to be suitable for the teachings of the present invention without departing from its base region.
SEQUENCE LISTING
<110>Beijing Yang Shen biology information technologies Co., Ltd
<120>Myocardial infarction biomarker miR-1283
<160> 10
<170> PatentIn version 3.3
<210> 1
<211> 22
<212> RNA
<213>Artificial sequence
<400> 1
ucuacaaagg aaagcgcuuu cu 22
<210> 2
<211> 22
<212> DNA
<213>Artificial sequence
<400> 2
tctacaaagg aaagcgcttt ct 22
<210> 3
<211> 18
<212> DNA
<213>Artificial sequence
<400> 3
ttcaccgacc aatgatat 18
<210> 4
<211> 19
<212> DNA
<213>Artificial sequence
<400> 4
ttacaccaca agataacac 19
<210> 5
<211> 18
<212> DNA
<213>Artificial sequence
<400> 5
ctgttgatgt gaagaagg 18
<210> 6
<211> 18
<212> DNA
<213>Artificial sequence
<400> 6
attgctgcta ggaagatt 18
<210> 7
<211> 18
<212> DNA
<213>Artificial sequence
<400> 7
gtgaggtgtt cagcatta 18
<210> 8
<211> 19
<212> DNA
<213>Artificial sequence
<400> 8
ggaaggtgat gaagatgac 19
<210> 9
<211> 19
<212> DNA
<213>Artificial sequence
<400> 9
gctattaggt attgctctc 19
<210> 10
<211> 18
<212> DNA
<213>Artificial sequence
<400> 10
atccatattg ttgccatt 18

Claims (10)

1. detect application of the miR-1283 preparation in diagnosing myocardial infarction reagent is prepared.
2. application according to claim 1, it is characterised in that miR-1283 sequence is shown in sequence table SEQ ID NO 1.
3. application according to claim 1, it is characterised in that diagnosing myocardial infarction reagent includes being based on high-flux sequence side Method and/or the transcription that miR-1283 in sample is detected based on quantifying PCR method and/or based on probing procedure, it is preferred that adopt With northern hybridizing methods, miRNA chip of expression spectrum, ribozyme protection analytical technology, RAKE methods, in situ hybridization, based on microballoon Flow cytometry sample in miR-1283 transcription.
4.miR-1283 application of the target gene in diagnosing myocardial infarction preparation is prepared.
5. application according to claim 4, it is characterised in that the target gene be DIANA-MICROT, MiR-1283 disclosed in MICRORNA.ORG, MIRDB, RNA22-HAS, TARGETMINER, TARGETSCAN-VERT database Target gene, it is preferred that target gene is HDAC4, PHC2, THOC5, IL17RA.
6. application according to claim 4, it is characterised in that diagnosing myocardial infarction reagent includes being based on high-flux sequence side Method and/or based on quantifying PCR method and/or based on probing procedure detect sample miR-1283 target genes transcription or be based on The expression of miR-1283 target genes in immunologic detection method detection sample.
7. application according to claim 4, it is characterised in that using northern hybridizing methods, miRNA express spectra cores MiR-1283 targets in piece, ribozyme protection analytical technology, RAKE methods, in situ hybridization, bead-based flow-cytometry detection sample The transcription of gene, or using the expression of miR-1283 target genes in ELISA and/or colloidal gold strip detection sample.
8. the application according to any one of claim 3,6,7, it is characterised in that sample is peripheral blood.
9. raise miR-1283 transcription and/or promote miR-1283 active reagent in preparation prevents and treats myocardial infarction preparation Application.
The inhibitor of 10.miR-1283 target gene is preparing the application in preventing and treating myocardial infarction preparation, it is characterised in that described Target gene is HDAC4, PHC2, THOC5, IL17RA.
CN201710592044.1A 2017-07-19 2017-07-19 Myocardial infarction biomarker miR 1283 Withdrawn CN107312851A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710592044.1A CN107312851A (en) 2017-07-19 2017-07-19 Myocardial infarction biomarker miR 1283

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710592044.1A CN107312851A (en) 2017-07-19 2017-07-19 Myocardial infarction biomarker miR 1283

Publications (1)

Publication Number Publication Date
CN107312851A true CN107312851A (en) 2017-11-03

Family

ID=60178222

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710592044.1A Withdrawn CN107312851A (en) 2017-07-19 2017-07-19 Myocardial infarction biomarker miR 1283

Country Status (1)

Country Link
CN (1) CN107312851A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019153241A1 (en) * 2018-02-09 2019-08-15 深圳华大生命科学研究院 Single nucleotide polymorphism loci associated with major adverse cardiovascular events and application thereof
WO2019227687A1 (en) * 2018-05-29 2019-12-05 中国科学院深圳先进技术研究院 Mirna inhibitor for hdac4 signaling pathway and overexpression method and use thereof
US11718880B2 (en) 2018-07-03 2023-08-08 Beijing Medintell Biomed Co., Ltd Marker and diagnosis method for noninvasive diagnosis of myocardial infarction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011131354A1 (en) * 2010-04-20 2011-10-27 Febit Holding Gmbh Complex mirna sets as novel biomarkers for an acute coronary syndrome
WO2012119051A2 (en) * 2011-03-02 2012-09-07 Groove Biopharma Corporation Enhanced biodistribution of oligomers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011131354A1 (en) * 2010-04-20 2011-10-27 Febit Holding Gmbh Complex mirna sets as novel biomarkers for an acute coronary syndrome
WO2012119051A2 (en) * 2011-03-02 2012-09-07 Groove Biopharma Corporation Enhanced biodistribution of oligomers

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019153241A1 (en) * 2018-02-09 2019-08-15 深圳华大生命科学研究院 Single nucleotide polymorphism loci associated with major adverse cardiovascular events and application thereof
WO2019227687A1 (en) * 2018-05-29 2019-12-05 中国科学院深圳先进技术研究院 Mirna inhibitor for hdac4 signaling pathway and overexpression method and use thereof
US11718880B2 (en) 2018-07-03 2023-08-08 Beijing Medintell Biomed Co., Ltd Marker and diagnosis method for noninvasive diagnosis of myocardial infarction

Similar Documents

Publication Publication Date Title
KR101987358B1 (en) Novel Biomarkers For Diagnosing Liver Cancer and Uses Thereof
CN101988060A (en) Marker for detecting colon and rectum cancer as well as detection method, kit and biological chip thereof
CN107312852A (en) Myocardial infarction diagnosis mark compositions
CN103703142A (en) Methods of detecting lung cancer
WO2016186987A1 (en) Biomarker micrornas and method for determining tumor burden
CN107674916B (en) Application of circular RNA in colorectal cancer biomarker
AU2012351524A1 (en) Methods for diagnosis and therapeutic follow-up of muscular dystrophies
CN109666743B (en) A kind of cervical carcinoma molecular marker and its application
WO2012072750A1 (en) Method for predicting the outcome of colon cancer by analysing mirna expression
CN105176983A (en) Kit for detecting esophageal squamous carcinoma associated serum miRNAs genes
CN107312851A (en) Myocardial infarction biomarker miR 1283
MX2010012542A (en) Methods for assessing colorectal cancer and compositions for use therein.
CN106244688B (en) A kind of marker for assessing adenocarcinoma of colon risk
CN109022583A (en) Hsa_circ_0021977 is preparing the application on Diagnosis of Breast cancer product
CN107058579A (en) Adenocarcinoma of lung related miRNA, composition and its application
CN107299129B (en) Application of circulating nucleic acid as breast cancer biomarker
KR101381894B1 (en) Serum miRNA as a marker for the diagnosis of lymph node metastasis of gastric cancer
CN105734155B (en) Chondroblastic osteosarcoma Disease-causing gene and its application
CN107254537A (en) The application of miR 1912 and its target gene in diagnosis and treatment myocardial infarction
CN105664163B (en) Application of the mir-5010 and its maturation miRNA in preparation osteosarcoma diagnosis and treatment preparation
CN107164546A (en) MiRNA, composition and its application in diagnosing the illness
CN107164550A (en) A kind of reagent for detecting myocardial infarction and its application
CN109161596B (en) The application of miR-129 and its target gene in detection adenocarcinoma of lung
CN105838804A (en) MiR-17-5p hematological malignancy auxiliary diagnosis reagent and application
CN109652529A (en) Osteoporosis specificity miRNA, composition and its diagnostic use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing

Applicant after: BEIJING MEDINTELL BIOMED Co.,Ltd.

Address before: 100080 Beijing city Haidian District Shanyuan Street No. 1 cubic court building room 3103

Applicant before: BEIJING MEDINTELL BIOMED Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20191212

Address after: Room 2503, Qianshan building, building D2, Qingdao International Innovation Park Phase II, No. 1, Keyuan Weiyi Road, Laoshan District, Qingdao, Shandong Province

Applicant after: Qingdao Yangshen biomedical Co.,Ltd.

Address before: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing

Applicant before: BEIJING MEDINTELL BIOMED Co.,Ltd.

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20171103